# Pizarra — PT-pseudo_1a4e0cf3b927 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_1a4e0cf3b927
Task: 1

Encounter: Urology - outpatient on 24 Feb 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 7.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.427 ng/mL²
  - PSA velocity: 1.15 ng/mL/yr
  - Prior PSA: 6.3 ng/mL
  - Prostate volume: 16.4 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8631027 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: Iodinated contrast (mild)
  - Additional notes: PSA 7 ng/mL. PI-RADS 5. PSAD 0.43. Prostate volume 16 mL. DRE nodus. csPCa 0.86.

Vitals: weight 84 kg, height 175 cm, BMI 27.4, BP 116/70 mmHg, HR 56 bpm. Smoking: Current smoker (37 pack-yr).

Chief complaint: Persistent elevation of prostate-specific antigen alongside a history of biopsy-confirmed malignancy prompted this clinical review.

History: A 74-year-old married tram driver who shares a home with his partner came to attention after routine primary care screening flagged a rising prostate-specific antigen level. He endorses mild lower urinary tract symptoms, tallying an IPSS of 6, characterized by slight nocturia and a weak stream, while explicitly denying pelvic pain or hematuria. Daily walks lasting 45 minutes sustain his activity level, and he abstains from alcohol entirely. A 37 pack-yr smoking history remains on record. Aside from a 2011 laparoscopic cholecystectomy, his medical background is clear. He notes occasional knee stiffness from prolonged standing on the tram platform, though swelling or inflammatory signs are absent. An Arabic interpreter will be present at our upcoming consultation to guarantee precise communication.

Physical examination: DRE — texture: firm, irregular Nodus (~1.5 cm) in the right lateral lobe; mobility: fixed; asymmetry: localized to the right, with the remainder of the gland maintaining symmetric architecture. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are clear. Peripheral lymph nodes are non-palpable, and hepatosplenomegaly is absent. Vital signs register at 116/70 mmHg blood pressure and 56 beats per minute heart rate. Body mass index stands at 27.4 kg/m².

Patient info: tram driver; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 45 min/day; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.50 +/- 0.21   (95% CI 0.11-0.88)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 5.4 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=7.0, age=74.0, psad=0.427, dre_ord=1.0, vol=16.4, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5, PSA=7.0, prior biopsy Positive, csPCa probability=0.8631027) and failed to incorporate the crucial context of the retrieved documents, such as the specific MRI findings, PSA trajectory, or laboratory panel details.
Specifically, the prior cannot weigh the significance of the PI-RADS 5 score against the prior positive biopsy status, nor can it assess the clinical relevance of the rising PSA velocity (1.15 ng/mL/yr) in the context of the retrieved lab results.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a wide uncertainty interval (0.50 +/- 0.21). This wide interval indicates the classifier is genuinely unable to distinguish between biopsy and no biopsy based on the limited input. The suggestion could be wrong because the prior ignores the guideline criterion that states the decision must be based on retrieved documents regarding lesion change or surveillance necessity. Furthermore, the prior does not account for the specific risk stratification provided by the guideline search regarding PI-RADS 5 lesions.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
laboratory panel - full panel
previous GP / urology notes - for documentation of prior biopsy status
The retrieval of the radiology report is critical because the guideline states that a stable MRI (PRECISE 1-3) might exclude a repeat biopsy, which is a factor the prior cannot assess.

GUIDELINE ANCHOR
The guideline search indicates that the decision must be based on whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether surveillance is due.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_1a4e0cf3b927", "radiology_report": "Subject: Multiparametric MRI Prostate | Date: 12 February 2025 | Facility: Bravis Ziekenhuis\n\nClinical Context:\nA 74-year-old male with a documented PSA of 7.0 ng/mL and a prior biopsy bucket \"Positive\" for ISUP GG 2 disease. Scan ordered to reassess for active malignancy.\n\nFINDINGS:\nProstate volume measures 16.4 mL. T2-weighted sequences highlight a sharply demarcated, markedly hypointense focus spanning roughly 18 x 15 x 12 mm within the right mid-gland peripheral zone. Diffusion-weighted imaging shows pronounced restriction, mirrored by low ADC signal. Dynamic contrast studies capture early, focal, and intense enhancement against the adjacent parenchyma. Capsular integrity remains intact with no extraprostatic extension or seminal vesicle invasion. Pelvic lymph nodes appear normal in size and shape. Bone marrow signals are unremarkable.\n\nIMPRESSION:\nPI-RADS 5 lesion in the right mid-gland peripheral zone, highly suspicious for clinically significant prostate cancer.\nPSA density: 0.427 ng/mL/mL.\ncsPCa predicted probability 0.8631027."}
get_psa_trend
{"case_id": "PT-pseudo_1a4e0cf3b927", "psa_trend": [{"date": "Mar 2022", "val": 3.1}, {"date": "Dec 2022", "val": 1.1}, {"date": "Sep 2023", "val": 5.6}, {"date": "May 2024", "val": 4.5}, {"date": "Feb 2025", "val": 7.0}]}
get_previous_notes
{"case_id": "PT-pseudo_1a4e0cf3b927", "previous_notes": [{"date": "29 Jun 2024", "author": "Dr. R. van den Berg (GP)", "text": "The most recent measurement from May 2024 recorded a PSA of 6.3 ng/mL, continuing a steady climb since initial detection. All routine bloods and liver function tests remain within acceptable limits for his age. A urology follow-up has been booked to review the persistent elevation and prior histological confirmation."}]}
get_lab_results
{"case_id": "PT-pseudo_1a4e0cf3b927", "laboratory_results": [{"name": "PSA", "val": "7.0 ng/mL", "date": "12 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.20 ng/mL", "date": "12 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "17%", "date": "12 Jan 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "14.9 g/dL", "date": "12 Jan 2025", "flag": ""}, {"name": "WBC", "val": "7.2 x10^9/L", "date": "12 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "165 x10^9/L", "date": "12 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "87 umol/L", "date": "12 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "12 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "15.8 nmol/L", "date": "12 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "61 U/L", "date": "12 Jan 2025", "flag": ""}, {"name": "LDH", "val": "182 U/L", "date": "12 Jan 2025", "flag": ""}]}

NOT RETRIEVED
The specific ISUP grade group or Gleason score of the prior biopsy is not documented in the retrieved documents, which is needed to assess the characterization problem.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right mid-gland peripheral zone, highly suspicious for clinically significant prostate cancer.
- PSA trend: Rising PSA velocity of 1.15 ng/mL/yr, with a recent jump to 7.0 ng/mL.

AGAINST sampling this patient now:
- Previous notes: Patient is on a follow-up protocol after a prior biopsy confirmation.

WHERE THIS LEANS
The evidence strongly suggests sampling is warranted due to the high-risk MRI finding (PI-RADS 5) and the rising PSA velocity, which contradicts the statistical prior's suggestion of no biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the retrieved MRI report shows a PI-RADS 5 lesion, which is a high-risk finding that was not characterized by a prior ISUP grade. The rising PSA velocity of 1.15 ng/mL/yr further suggests active disease progression, which is a factor that would change management. Since the prior grade is undocumented, sampling is warranted to establish the current pathological status and guide definitive treatment planning.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
